



FIG. 1b




FIG. 1a




FIG.1d




FIG.1c

3/17




FIG. 2c

FIG. 2b

FIG. 2a




FIG. 2e

FIG. 2d

5/17




FIG. 3

6/17




FIG. 4

7/17





FIG. 5



9/17

- E:T RATIO 60
- E:T RATIO 30
- ▨ E:T RATIO 15
- ▩ E:T RATIO 7.5

L1210 TARGETS (T)




FIG. 6B

10/17




FIG. 7

11/17




FIG. 8a







FIG. 8b

12/17




FIG. 10


Insulin + hybridoma




allo MLR Proliferation




allo MLR IL-2




allo MLR +/- anti B7






15/17




- A**
- ▲ L1210/P815 (7X)
 - ▼ L1210/HY38/GM-CSF (7X)
 - ◆ P815/P815 (7X)
 - P815/HY38/GM-CSF (3X)
 - P815/HY38/GM-CSF (7X)
- B**
- ▼ untreated mice + P815 ascite
 - surviving mice treated with HY38/GM-CSF (7X) + P815 ascite
 - surviving mice treated with HY38/GM-CSF (3X) + P815 ascite






Proliferation of lymph node cells (Thymidin uptake)



Interleukin 2 secretion



Interferon gamma secretion

